[1] Jim O, Shitij K.Schizophrenia[J].Lancet, 2009, 374:635-645. [2] Wojciak P, Remlinger-Molenda A, Rybakowski J.Stages of the clinical course of schizophrenia-staging concept[J].Psychiatr Pol, 2016, 50(4):717-730. [3] Chan C K, Di X, McAlonan G M, et al.Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia:an activation likelihood estimation meta-analysis of illness progression[J].Schizophr Bull, 2011,37 (1):177-188. [4] Ucok A,Direk N,Koyuncu A,et al.Cognitive deficits in clinical and familial high risk groups for psychosis are common as in first episode schizophrenia[J].Schizophr Res,2013,151(1-3):265-269. [5] 赵珊珊,张天宏,唐莺莹,等.精神病临床高危综合征与首发精神分裂症患者的神经认知功能比较研究[J].神经疾病与精神卫生杂志,2014,14(2):130-133. [6] 贾竑晓,唐永怡,江镇康,等.健脾补肾法治疗精神分裂症认知损害的临床观察[J].北京中医药大学学报,2004,27(5):81-83. [7] 周方,唐永怡,张继志,等.四君子汤治疗精神分裂症记忆损害的临床观察[J]. 首都医科大学学报,2008,29(4):428-430. [8] 麦克拉申.精神病风险综合征:诊断和随访手册[M].宁玉萍,译.北京:人民卫生出版社,2012:174-236 [9] Cao A,Shen T,Li H,et al.Dysfunction of cognition patterns measured by MATRICS consensus cognitive battery (MCCB) among first episode schizophrenia patients and their biological parents[J].Shanghai Arch Psychiatry, 2017,29(3):154-160. [10] Zhou F C, Xiang Y T, Wang C Y, et al. Characteristics and clinical correlates of prospective memory performance in first-episode schizophrenia[J]. Schizophr Res, 2012, 135(1-3):34-39. [11] 朱虹,尹冬青,张晓钢,等.精神分裂症前驱期中医证素特点研究[J].中华中医药杂志,2018,33(4):1303-1307. [12] 尹冬青,贾竑晓,张晓钢.贾竑晓益肾平肝法治疗精神分裂症前驱期的临床经验[J].中华中医药杂志,2017,32(12):5395-5398. [13] 吴燕,孙作厘,马超,等.中药益肾平肝方对脱髓鞘模型小鼠社会交互行为的影响及作用靶点[J].首都医科大学学报,2019,40(2):209-213. [14] Devinsky O, Laff R. Callosal lesions and behavior:history and modern concepts[J].Epilepsy Behav, 2003,4(6):607-617. [15] 季莉,袁宏伟,赵幸福,等.阿立派唑对精神分裂症认知功能及神经元特异性烯醇化酶水平的影响[J].中国健康心理学杂志,2013,21(2):167-169. [16] 刘文庭,杨云霞,赵涛,等.阿立派唑对精神分裂症患者认知功能的影响[J].中国行为医学科学,2006(6):510-511. [17] 徐晓津,房茂胜,缪楹,等.阿立派唑治疗精神分裂症伴抑郁的效果及对血清催乳素和糖脂代谢的影响[J].解放军医药杂志,2019,31(3):76-79. [18] 庄红艳,毕葳,贾竑晓.具有神经保护作用的中药有效成分研究进展[J].首都医科大学学报,2014,35(2):210-213. |